drug discovery

Atelier Therapeutics is a biopharmaceutical company dedicated to advancing human health through innovative approaches, with a primary focus on under-explored GPCR drug targets. Leveraging expertise in structural biology, computational chemistry, and machine learning, the team develops differentiated therapies addressing major unmet medical needs, focused on reducing chronic inflammation and enhancing neuronal function to promote vitality and longevity.

computational chemistrymachine learningstructural biology

Atomic AI operates at the intersection of artificial intelligence and RNA therapeutics, using machine learning and structural biology to develop RNA-centric medicines. Its proprietary R&D platform leverages ATOM-1, a foundation model for RNA that delivers precise predictions of RNA structure and function, integrated with in-house wet-lab assays. The company focuses on designing foundation models for RNA and developing RNA-targeted small molecules and RNA-based therapeutics.

machine learningmedicinal chemistryRNA structure and function predictionstructural biologywet-lab assays

Atomistic Insights brings together experts in protein dynamics, drug discovery, and AI to unlock undruggable targets and create breakthrough medicines. The company uses a physics plus AI approach to protein dynamics, aiming to reveal the complete story of protein function and address the fact that drug discovery is still blind to protein motion. Based in Atlanta, GA, it is backed by biotech advisors and investors.

AIprotein dynamics

Augment Therapeutics is an early-stage pharmaceutical research and development company headquartered in Lake Forest, California, USA and Hyderabad, Telangana State, India. It develops 'Enhanced' versions of widely used off-patent generic drugs using proprietary novel linker/prodrug technologies, including its BINARS self-immolative linker platform, targeting development through the USFDA 505(b)(2) regulatory route.

clinical researchpreclinical researchprodrug/linker technology developmentregulatory affairs (US FDA 505(b)(2))

Avantyx LLC is a women-owned startup company developing a therapeutic agent to prevent and restore peripheral nerve damage caused by chemotherapy and diabetes. Its research team identified a unique mechanism causing peripheral nerve damage and is working on a therapeutic drug targeting the root cause of neuropathy to prevent nerve damage and restore nerve function.

peripheral neuropathy researchsmall molecule drug discovery

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibition within the brain. Its work translates breakthrough discoveries spun out from Boston Children's Hospital, Harvard and Laval University. The company has a proprietary KCC2 discovery engine and began first-in-human trials in 2024 for its first-in-class oral KCC2 potentiator drug, AXN-027, designed to restore functional inhibition to treat epilepsy, pain and other CNS pathologies.

KCC2 discovery enginetarget biology

Azome Therapeutics is a drug discovery company developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway involved in diseases such as acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia. Its lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks an upstream priming signal in the aberrant activation of the NLRP3 inflammatory cascade. Initial indications target severe inflammatory pulmonary diseases with significant unmet need

development of NLRP3 inflammasome antagonists

BioCryst is a commercial-stage global biotechnology company founded in 1986, headquartered in Durham, North Carolina, with a regional office in Boston, Massachusetts. It focuses on drug discovery, development, and commercialization of oral small-molecule and injectable protein therapeutics for hereditary angioedema (HAE) and other rare diseases.

clinical trialscommercializationdrug development

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data using machine learning to translate human disease biology and advance precision medicines. Its Elion platform connects patient data from electronic medical records with experimental data captured in zebrafish models using proprietary computer vision to identify high-confidence drug targets. The company is advancing programs in cardiometabolic, neurological, and rare diseases, including familial dilated cardiomyopathy, atherosclerosis, and epilepsy.

computer visionin vivo validationmachine learningphenomicstarget discovery

BioSyntex Laboratories, LLC is a small, woman-owned drug discovery and design company developing nanotechnology-driven pharmaceuticals and hybrid therapeutics that combine biologically derived carriers such as vesicles, exosomes, and peptide ligands with small molecule payloads. Its platform targets neuroinflammation and infectious disease along the gut-brain axis, with delivery routes optimized for oral, intranasal, and vesicle-enabled CNS penetration. The company is advancing multiple drug candidates toward IND-enabling studies and welcomes collaborati

drug designnano-medicinepharmaceutical researchtargeted drug delivery

Bugworks is a clinical stage biopharmaceutical company set up in 2014 and incubated in C-CAMP, Bangalore. It develops affordable, accessible, novel therapies against infectious diseases and cancer, including a novel broad-spectrum antibacterial agent with a lead candidate in clinical trials and a portfolio of novel anticancer agents with a lead candidate ready for IND submission. It is headquartered in the USA with subsidiaries in India and Australia.

antibacterial agent developmentoncology therapeutics developmentsmall molecule therapeutics discovery

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. It is pioneering a precision medicine approach targeting specific TGF-β superfamily members and pathways in oncology, inflammatory/immune, fibrotic, and metabolic diseases.

biologics developmentbiomarker stratificationPK/PD modelingprecision medicinepreclinical developmentsmall molecule development

Camino Pharma is a San Diego-based startup company focused on discovering and developing first-in-class therapies for patients suffering from cancer and CNS disorders. They target signaling proteins based on emerging biological concepts and discover novel mechanisms for modulating these targets with small molecule drugs.

drug developmentsmall molecule drug discoverytarget biology

Aphios is a clinical-stage biotechnology company developing differentiated medicines through SuperFluids™ manufacturing and advanced drug delivery. Its lead program, Zindol®, is being prepared for Phase 3 development for chemotherapy-induced nausea and vomiting. The company holds 85+ issued patents and has received more than $20 million in NIH grant funding. Founder, President & CEO is Dr. Trevor P. Castor.

co-developmentdrug deliverydrug manufacturinglicensingnanotechnology drug formulation and deliverypathogen reductionpurificationsupercritical-fluid extraction and fractionationSuperFluids™ manufacturing

Cayman Chemical manufactures high quality biochemicals, assay kits, antibodies, and recombinant proteins. The company also offers contract services for custom chemical synthesis and analysis, assay development and screening, and drug discovery.

assay developmentassay screeningchemical analysiscustom chemical synthesis

Cayuga Biotech is a biopharmaceutical company developing first-in-class therapeutics that harness the body's innate ability to stop bleeding, aiming to address life-threatening hemorrhage including noncompressible hemorrhage and coagulation dysfunction. The company was founded to address significant unmet need using proprietary biomimetic science. Its founder invented CAY001.

drug developmenthemostasis and thrombosis research

Cellarity is a drug discovery company that aims to solve complex diseases with medicines designed to correct the dynamic cell state. Its integrated multi-omics and AI-powered discovery platform maps networks of cell and gene interactions to predict and design oral Cell State-Correcting therapeutics that regulate gene switch mechanisms to restore proper cell function. Cellarity was launched by Flagship Pioneering in 2019.

Artificial Intelligence and Machine Learningcomputational biologymedicinal chemistrymulti-omics

Celmatix Inc. is a US-based women's health biotech company dedicated to translating advances in female biology into novel therapeutics. Its discovery portfolio spans infertility, endometriosis, and ovarian aging, including a first-in-class oral FSH receptor agonist, a JNK inhibitor for endometriosis, and AMH-targeting antibodies. Celmatix was selected to receive a $3.5 million award from ARPA-H's Sprint for Women's Health.

therapeutic development

ClotProtect Therapeutics Limited is a UK therapeutics spin-out from the University of Leeds developing a first-in-class small molecule anti-fibrinolytic (CP-101) to treat acute haemorrhage. The company is currently in preclinical development, aiming to identify a clinical drug candidate, and its approach promotes clot formation through a novel molecule and mechanism with superior efficacy and potency to the current standard of care (TXA).

preclinical developmentsmall-molecule therapeutics

Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for the treatment of neuroinflammatory diseases including Multiple Sclerosis, Alzheimer's Disease, and brain bleeding events. The company is discovering and developing therapeutic compounds based on the apoE protein, small patented synthetic peptides of ten to seventeen amino acids with anti-inflammatory and neuroprotective activity. Cognosci purchased rights to an APOE-based compound from Duke University and has engineered over 500 new compounds.

clinical trial developmentcompound engineeringlead optimizationpreclinical development

Concarlo Therapeutics is a biotech company developing novel therapeutics to improve outcomes for cancer patients, using innovation in p27 biology. It is described as the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance. Its mission is to improve outcomes for patients with drug-resistant cancers by creating transformative therapies that control the p27 target.

computational biologymedicinal chemistrypeptide therapeuticspreclinical development

Cortexa Therapeutics is a neuroscience company developing therapies that target biological mechanisms shared across neurodegenerative diseases to restore neuronal homeostasis. Its first program, CRTX-101, targets calcium-permeable AMPA receptors (CP-AMPARs) as mediators of excitotoxic calcium overload in ALS. The company was founded by Nathan Cole following his ALS diagnosis at age 31 and is advised by a scientific board spanning motor neuron biology, ALS neurobiology and excitotoxicity, and translational neurodegeneration research.

neuroscience researchtherapeutic development

Courage Therapeutics is a neuroendocrine company co-founded by Dr. Roger Cone that translates discoveries and novel chemistries into therapeutic candidates targeting the MC4R receptor. Its lead candidate, CTX-B, is a weekly injectable for the treatment of melanocortin-4 receptor haploinsufficiency (MC4R HI), a genetic obesity with no approved targeted therapeutic options.

IND-enabling programsmedicinal chemistrypreclinical development

Crinetics Pharmaceuticals, Inc. is a global pharmaceutical company focused on discovery, development, and commercialization of novel therapeutics for endocrine disease and endocrine-related tumors. Its in-house R&D team develops novel molecules targeting the endocrine system and G-protein coupled receptors. The company aims to build the world's leading endocrine company.

commercializationdrug developmentGPCR-targeted drug discoveryR&D